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ABSTRACT: Poly(2-dimethylamino-ethylmethacrylate) (PDMAEMA) is a cationic polymer when dissolved in a 7.4 pH fluid.
Owing to its ionic nature, this polycation interacts with the negatively charged cell membrane surface of red blood cells (RBCs).
The electrostatic self-assembly of PDMAEMA on RBCs membrane can be employed for inducing the formation of a polymeric
shield camouflaging blood group antigens on RBCs as a valuable strategy for developing “universal RBCs” for blood transfusion.
The purpose of this research was to evaluate the camouflaging ability of PDMAEMA homopolymers and PDMAEMA-co-
poly(ethylene glycol) copolymers differing in molecular weight and architecture. Surprisingly, the PDMAEMAs caused a partially
masking, no masking, and sensitization of the same RBCs population. The MW and architecture of the polymers as well as
temperature of PDMAEMA-RBCs treatment influenced the results observed. Herein, the very particular reactivity of
PDMAEMAs and RBCs is analyzed and discussed.
1. INTRODUCTION
Cell surface engineering is a promising strategy for the
production of immunologically silent cells.1,2 Accordingly, if
cell plasma membranes are physicochemically modified to mask
or remove antigens, then cell immunogenicity will be reduced
or will totally disappear.1 Cell surface modification is a useful
approach for the most common type of cell transplantation, in
particular, for the transfusion of red blood cells (RBCs;
erythrocytes). Transplantation of erythrocytes is governed by
the main blood group antigens present on the cell membrane,
the ABH (ABO system) and D (Rh system) being the most
clinically significant.3,4
Because of blood grouping, transfusion requires mandatory
matching between blood donor and receptor to avoid any
possibility of antigen−antibody response that would induce an
immune-hemolytic reaction.5 However, although transfusion
laboratories perform highly reliable matching tests, mismatch-
ing can still occur (5.0 to 5.2 mismatches per 100 000
transfusions6); even if this inconvenience is prevented by the
use of type O RBCs, supplies of these cells are usually
insufficient in hospitals.7 To sort out this lack of universal
RBCs, cell surface modification has become a promising
strategy for production of silent RBCs.1,8
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Surface modification to produce silent RBCs has been
explored with two major approaches: the enzymatic cleavage of
antigens and the camouflaging of antigens by polymers.1 The
former relies on enzymatic cleavage of the monosaccharide A or
B antigenic sites to convert RBCs into type O cells (ECO-
RBCs).9,10 Although enzymatic cleavage has significantly
reduced the antigenic properties of RBCs,9,10 ECO-RBCs
have still shown reactivity to antibodies,1,10 but the main
drawbacks of this method are the difficulty of large-scale and
high cost of production of the requested enzymes.1
The other approach involves the formation of a polymeric
shield around RBCs by either covalent or electrostatic binding
of polymers. Covalent binding has been studied especially by
grafting poly(ethylene glycol) (PEG) polymer. This nonionic
polymer is largely used for RBC surface modification because of
its flexible structure and physicochemical properties that favor
the formation of a water-polymeric shield-inducing steric
repulsion of antibodies.1,11 However, although PEGylated
RBCs have been studied intensively, concerns still exist about
the total efficacy of PEG to mask cell antigens and due to the
rapid clearance of the PEGylated RBCs.1 Another method of
forming a polymer shield relies on the self-assembly of cationic
polymers on the RBC surface,12,13 taking advantage of negative
charges on the carbohydrate structures on the RBC surface,
including those on antigens. Polymeric self-assembly by layer-
by-layer (LbL) method has also been used to grow
polyelectrolyte layers to modify RBCs. When the LbL method
is applied on the erythrocyte surface, a polycation-based layer is
formed first, then the excess of free positive charges is used to
adsorb a subsequent anionic-based layer; this process can be
repeated to increase the thickness of the coating. This method
has been reported to adopt a double layer of chitosan-g-
phosphorylcholine-sodium hyaluronate and poly-L-lysine
(PLL)-g-PEG-sodium alginate in view to block anti-A antibod-
ies.12,13 Even though LbL is promising, it may increase the risk
of altering the membrane properties, in particular, their
flexibility. In this respect, a single polymer layer made by a
simple one-step method, as proposed by Elbert and Hubell, is
an attractive alternative. These authors have performed self-
assembly of PLL-g-PEG on RBCs blocking lectin-induced
hemagglutination.14 Herein, using self-assembly, we have
investigated poly(2-dimethylamino-ethymethacrylate)
(PDMAEMA)-based polymers to camouflage RBC antigens.
The PDMAEMA sequence, partially cationized at pH 7.4, is
expected to anchor the synthetic macromolecule on the RBC
surface. These polymers include PEG grafts to form a steric
barrier, promote antibody repulsion, and avoid cell aggregation.
Utilizing this polymer family, Riquelme et al. have already
reported that PDMAEMA-co-MAPEG copolymers (MW
29 100 and 30 700) did not alter the morphological and
rheological properties of RBCs up to a polycation concen-
tration of 250 μg/mL.15 Moreover, those polymers induced
partial masking of antigens A and B and of glycophorin A
(GPA). Additionally, a previous hemocompatibility study of
PDMAEMAs with whole human blood has shown their safety
up to 100 μg/mL.16 However, there is still a lack of
understanding of PDMAEMA-RBC interaction and the effect
of PDMAEMAs on RBC camouflage. In the present study, we
assessed the immune-camouflaging ability of PDMAEMA
homopolymers of differing MWs. Their properties have been
compared with three distinct PDMAEMA-co-MAPEG copoly-
mers to better understand the correlation between the
macromolecular features of these polymers and their effect on
antigen masking. Immunomasking was evaluated by adopting
fluorescent antiglycophorin A antibody and using flow
cytometry to quantify cell immunoprotection considering
different polymer concentrations and performing the polymeric
coating at temperatures ranging between 25 and 37 °C.
2. MATERIALS AND METHODS
2.1. Materials. 2-(Dimethylamino) ethyl methacrylate (DMAE-
MA) and PEG α-methoxy, ω-methacrylate (MAPEG), Drabkin’s
reagent (cyanmethemoglobin), Brij 35, and bovine hemoglobin were
purchased from Sigma-Aldrich (Bornem, Belgium). Fluorescein
isothiocyanate (FITC) mouse monoclonal antibody (Mouse IgG1)
antihuman GPA (CD235a) (aGPA) was purchased from Invitrogen
(Merelbeke, Belgium). Phosphate-buffered saline (PBS) pH 7.4 was
prepared with KH2PO4, 1.4 mM; Na2HPO4, 10 mM; NaCl, 137 mM;
and KCl, 2.7 mM. All other chemicals and reagents were of analytical
grade.
2.2. Synthesis and Characterization of PDMAEMA-Based
Polymers. The PDMAEMA-based polymers were synthetized by a
solvent-free, atom-transfer radical polymerization (ATRP) method.
Synthesis, characterization, and purification of polymers were
performed as reported elsewhere.16 After purification, each polymer
was dissolved in PBS (stock solution 1 mg/mL) and stored at −20 °C
until their use for the experiments.
2.3. Blood Collection and RBC Suspension. Type A blood
group samples were employed to avoid any variation between blood
groups. Blood samples were originated from healthy donors of the Red
Cross Blood Transfusion Department in The Central Hospital of the
University of Lieg̀e. Blood was collected in 3.2% citrated 4.5 mL tubes.
After collection, blood was centrifuged for 10 min at 3000 rpm to
separate the RBCs from the plasma. The erythrocytes were washed
three times with PBS under the same conditions of centrifugation.
Finally, a 5% RBC (∼6.8 × 105 RBCs/μL) suspension (RBC
suspension) was prepared for the experiments. All experiments were
done within 2 h of collection. This study received the approval of the
Ethics Committee of the Medical Faculty of Lieg̀e.
2.4. Polymeric Coating of the RBCs. In brief, in a 2 mL
cylindrical microcentrifuge polypropylene tube, 150 μL of the RBC
suspension was added to an equal volume of a polycation solution.
The cell suspension was mixed immediately afterward using three up-
and-down movements to avoid any gradient concentration of the
polymer. Immediately after, the cell suspension was incubated under
lateral agitation (CAT model M5, CAT Ingenieurbüro, Staufen, DE)
at a rate of 36 rpm for 1 h at 37 °C. This second mixing was performed
at room temperature (RT°; 25 °C) for the homopolymers, whereas for
the copolymers, three distinct temperatures (25, 30, and 37 °C) have
been investigated. After that, 1 mL of PBS was added to the treated
RBCs to wash and centrifuge them (Mini Spin Plus Microcentrifuge,
Eppendorf) for 10 min at 600 rpm. This step was repeated twice
(three washing steps in total). Then, the RBCs were resuspended at
5% concentration.
2.5. Evaluation of Fluorescence in Treated RBCs. After adding
5 μL of aGPA (4.5 μg/mL) to 50 μL in a conic Eppendorf tube (1.5
mL) of either treated or control erythrocyte suspension, the
PDMAEMA RBCs and native RBCs (nontreated) were incubated
for 30 min at 4 °C (lateral agitation, 300 rpm). After incubation, the
cells were gently washed with 1 mL of PBS and centrifuged at 1200
rpm for 5 min at RT° (Mini Spin Plus Microcentrifuge). Because we
used an FITC-conjugated antibody, only a washing step was
performed.17 Samples were analyzed 30 min after being stored in
darkness at RT.
All samples were analyzed with a FACSCalibur flow cytometer at
RT° (FSC Volt 800; SSC volt 447; FL1 615, FL2 550, FL3 650)
(Becton Dickinson, Erembodegem, Belgium). Collected data were
analyzed with WinMDI 2.8 software (Purdue University Cytometry
Laboratories, West Lafayette, IN). Native RBCs were used as a sample
reference for size distribution and granularity, and the native RBCs
incubated with aGPA were used as sample reference for fluorescence
(mean fluorescence intensity (MFI)). The experiments were
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performed in triplicate and with at least two repetitions. A one-way
ANOVA and Tukey-Kramer HSD were performed to identify possible
significant statistical differences between MFI and percentage of RBCs
(RBCs number) of PDMAEMA-RBCs and untreated RBCs.
2.6. Evaluation of RBCs by Optical Microscope. When
required, the treated RBCs were observed by an optic microscope as
reported by Cerda-Cristerna et al.16 In brief, 10 μL of PDMAEMA-
RBCs (5% concentration) was diluted in 990 μL of PBS in a 1.5 mL
Eppendorf tube. An aliquot (40 μL) of that suspension, dropped into a
flat-bottomed, 96-well multiplate, was observed with an inverted
microscope (Inverso-TC, CETI) at ×25 magnification and imaged
with a digital camera (VisiCam 5.0, VWR, Leuven, Belgium). Two
repetitions were performed using distinct polymer batches.
3. RESULTS AND DISCUSSION
3.1. Synthesis and Characterization of PDMAEMA. It
should be stressed that ATRP has as main advantageous to
tailor well-defined PDMAEMA-based polymers for evaluating
their coating properties. Control of the molecular features of
these macromolecules was particularly important in view to be
able to correlate their macromolecular features (architecture,
MW, polydispersity) and their hemoreactivity. Table 1 shows
the characteristics of the PDMAEMA-based polymers consid-
ered in this study. Two linear PDMAEMA homopolymers
(coded P1 and P2) were selected in view to assess the influence
of the difference in molecular length of the polycation sequence
on the masking ability of PDMAEMA on RBCs. Two palm-tree
PDMAEMA-co-MAPEG copolymers (coded P3 and P4) and a
random PDMAEMA-co-MAPEG copolymer (coded P5) have
been investigated to evaluate the steric effect brought by the
polyethylene oxide sequence on antigen masking ability. In the
case of P3 and P4, they have palm-tree architecture, but P4 has
higher PEG content and longer PEG chains than P3. The
random P5 has statistically distributed PEG with length
identical to P3.
To avoid any side reactivity of the blood with monomer,
catalyst, or initiator residues, we paid special attention to purify
these polymers extensively, having been submitted to three
successive and complementary extraction steps. After purifica-
tion, Cu residue, determined by ICP/MS, was found to be 158
± 17 ppm. Monomer residue, estimated from 1H NMR
analysis, was below 0.1%.
3.2. Effect of PDMAEMA Homopolymers on RBCs.
Antigen GPA was selected to evaluate camouflaging because it
furnishes most of negative charges of the RBC membrane and
represents a major protein component of the RBC’s surface
with a number of copies in the range of 1 million/cell with few
variation in density compared with the ABO antigens.18 Before
considering the copolymers, we were curious to explore the
effect of only the PDMAEMA polymer for camouflaging of
RBCs and compare it with the copolymers. Indeed, surfaces
modified with PDMAEMA have displayed antifouling proper-
ties.19 This resistance to protein adsorption has been achieved
after elimination of electrostatic interactions, thus playing on
either ionic strength or pH. For that purpose, we assessed
coating the RBCs with either P1 or P2 (P1-RBCs and P2-
RBCs, respectively), considering two polycation concentra-
tions: 2 and 10 μg/mL. aGPA-incubated RBCs as well as native
RBCs were adopted as controls. (See representative dot plots in
Figure 1.)
Size distribution and granularity of untreated RBCs have
been mainly observed on the lower left [LL] quadrant of the
dot plots with ∼15% of events noticed on the upper left [UL]
(Figure 1A). A similar cell distribution pattern was also
recorded after treatment with P1, P2, or aGPA, but surprisingly
enough, when the P2-RBCs were incubated with aGPA, both
size distribution and granularity were incremented. This
augmentation, noticed on the right side of the dot-plots
(upper right [UR] and lower right [LR] quadrants) (Figure
1B), typically results from a cell aggregation.
In view of understanding the origin of cell aggregation
mediated by aGPA, we included two additional controls. The
first relied on incubating PDMAEMA-RBCs with bovine serum
albumin (BSA), a protein present at 4 mg/mL concentration in
the reagent solution of the aGPA. Indeed BSA could potentially
act as a cross-linker between RBCs due to its size and global
negative charge at neutral pH. If PDMAEMA adsorbed to the
RBC membrane, then we would anticipate that its positive
domains could interact with the anionic sites of BSA, therefore
promoting cell aggregation. We also included another control
consisting of PDMAEMA-RBCs with a nonspecific RBC
antibody, anti-CD45 (aCD45). This mouse IgG1 antibody,
although having macromolecular features similar to aGPA
(unlike BSA), is not likely to interact with human RBCs. In the
case of positive answer, this response would result from
nonspecific interaction and should proceed via FC fragment.
For a better and more quantitative interpretation of the results,
the percentage of events on the right side of each dot plot was
subtracted from the percentage of events on the left side.
Table 1. Characteristics of the PDMAEMA Homopolymers
and Copolymersa





P1 linear PDMAEMA 10 000 1.19 100
P2 linear PDMAEMA 26 400 1.17 100
P3 poly(DMAEMA-block-
MAPEG)
30 000 1.20 85 480
P4 poly(DMAEMA-block-
MAPEG)
30 700 1.18 75 3050
P5 poly(DMAEMA-
random-MAPEG)
29 000 1.52 51 480
aRelative average MWs (Mw and polydispersity index (PDI) were
determined by size exclusion chromatography in THF/triethylamine
(TEA) (2.5%) against polystyrene standards. bMolar % of
PDMAEMA was determined by 1H NMR in CDCl3.
Figure 1. Dot plots, granularity versus size distribution (y axis vs x axis,
respectively) noticed during the analysis of (A) native RBCs and (B)
P2 10 μg/mL-RBCs-aGPA. The RBCs incubated with only aGPA or
with only P1 and P2 presented a RBCs distribution similar to A.
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Accordingly, if cell aggregation occurs, then the percentage of
RBCs (% RBCs) on the left side would decrease. Interestingly,
the results demonstrated that neither BSA nor aCD45 affected
the % RBCs (Figure 2). This evidence supports the selectivity
of RBC aggregation due to specific GPA recognition. This
immune-cell agglutination was corroborated by optical
microscopy. As highlighted on Figure 3, the comparison of
the microscopic pictures confirms that the specific RBC
agglutination is observed only under the P2-aGPA-RBC
conditions.
These observations showed that PDMAMEA with a MW
above 10 000 and at concentrations of at least 2 μg/mL
selectively enhances cell agglutination following immune
recognition of the GPA antigens on the RBC surface. As a
consequence of the formation of polyelectrolyte complexes
between PDMAEMA and anionic sites of RBC’s membrane,
with as result a reduction of their zeta potential,20,21 this
unexpected result might be explained the enhancement in
immune-specific RBC aggregation.22,23 It should be stressed
that in the range of PDMAEMA concentration and MW
considered in this section, we are far from totally neutralizing
the RBCs. We have observed that P1 at 10 μg/mL reduces the
RBCs’ electrophoretic mobility from −2.85 to −2.50 μm·cm/
volts without inducing cell aggregation (data not published); a
similar effect of P2 can evidently be expected. In addition to the
effect of PDMAEMA on the negative charges of RBCs, the
aGPA could also participate in the reduction of zeta potential.
GPA is a sialoglycoprotein composed of an intracellular, a
transmembrane, and an extracellular domain.24 Because the
latter domain contains a high sialic acid content, GPA is the
main source of negative charges representing ∼60% of the
RBCs’ negative surface charge.24 Accordingly, the principal
Figure 2. Evolution of the RBC percentages of the left side FACS
events after subtraction of right events noticed for RBCs treated with
PDMAEMA and incubated with aGPA, BSA, or aGPA. NRBCs: native
RBCs; aGPA/RBCs: RBCs incubated with aGPA. Light gray bar: P1-
treated RBCs; black bar: P2-treated RBCs. *: statistically significant
differences between that sample and native RBC. #: statistically
significant differences between P2 and its corresponding P1. % RBCs
of each bar is the average of at least two distinct replicas.
Figure 3. Optical micrographies (×25) of RBCs: (A) control sample (Similar observations were done for RBCs treated only with P1 or P2); (B)
RBCs treated with aGPA; (C) RBCs treated with P1 (10 μg/mL) and aGPA; and (D) RBCs treated with P2 (10 μg/mL) and aGPA. Bar represents
100 μm.
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function of GPA is induction of cell-to-cell repulsion, avoiding
RBC aggregation.17 Taking into account he fact that aGPA is an
IgG1 antibody with an isoelectric point in the range of 6.4 to
9.0,25 its binding to GPA should contribute to neutralization of
the RBC membrane under the conditions adopted within our
experiment. Moreover, antibody binding may affect the
electrical charges of the antigen.25
An additional factor that should help to enhance cell
aggregation relies on the fact that the partial neutralization of
negative surface charges originally expressed by RBCs should
also facilitate cell bridging due the double valence of aGPA-IgG.
Indeed, a reduction of RBCs zeta potential should promote cell
bridging through the interaction of the two binding sites of the
IgG molecules with antigens expressed by the two adjacent
cells. Therefore, aGPA molecules might act as a cell cross-
linkage to promote RBC aggregation. It has been reported that
other polycations, such as protamine and polybrene, also
promote RBC antibody detection because of their ability to
reduce intercellular distance.26,27 Although these assumptions
will need experimentations to support them, it would be
valuable to valorize these observations as a mean of enhancing
immunoreaction for diagnostic purposes.
We also assessed the ability of homopolymers to mask the
cells. This property has been analyzed based on two main
criteria, that is, the percent of immunomasked RBCs in a given
population of normal RBCs and the extent of antigen covering/
immunoprotected cell. These two parameters, identified as
efficiency and effectiveness, respectively, have been determined
from FACS diagrams as typically reported in Figures 4 and
5A,B.
The native RBCs incubated with aGPA presented a
homogeneous cell population showing a signal of fluorescence
that was used as a reference point to determine the percentage
of camouflaged RBCs. Surprisingly, PDMAEMA-RBCs pre-
sented a cell population with distinct regions of fluorescence.
To analyze those samples, we determined four clockwise
regions (Figure 4) based on the reference point of fluorescence
(aGPA/RBCs): Region 1 (R1): events located there were
exclusive of the analysis because they represented cell
aggregates without value for the interpretation of other data;
Region 2 (R2) corresponded to a higher MFI. If PDMAEMA-
RBCs were located there, then they were considered to be
sensitized RBCs (sRBCs); Region 3 (R3) presented cells with
MFI similar to the control RBCs; therefore, PDMAEMA-RBCs
located there were considered to be noncamouflaged RBCs
(ncfRBCs); and Region 4 (R4): if PDMAEMA-RBCs were
present, then they were considered to be camouflaged RBCs.
The percentage of R2, R3, and R4 cfRBCs was determined
by the number of events located in each of these regions
(Figure 5). For discussion purposes only, we identified the
sRBCs, ncfRBCs, and cfRBCs as subpopulations.
Although the camouflage efficiency remained low for all
conditions assessed, some dependence was observed as a
function of PDMAEMA concentration and MW (Figure 5A).
Both an increase in polycation concentration and in MW raised
the antigen masking efficiency with a maximum effective
protection noticed (15.4 ± 3.7% cfRBCs) for P2 at 10 μg/mL.
To evaluate the camouflage extent per cell, that is, the
immunomasking effectiveness, we compared the percentage of
mean fluorescence intensity (% MFI) of the protected cells
(calculated by reference to the MFI of the native cells incubated
with aGPA and considered as 100%). This parameter indicated
that although most of the blood cells (up to 95%) kept GPA
antigens accessible to the antibody, the protected cells
demonstrated a strong reduction in % MFI (up to 80%
reduction compared with the control cells) (Figure 5B).
Although no total camouflaging was observed, this series of
experiments highlights interesting findings on the heterogeneity
in reactivity of the RBC population to the PDMAEMA’s
macromolecules.
Before discussing these points, we have estimated whether
the number of polycation molecules added to the RBCs was
enough to cover the entire surface of the cells. For that
calculation, we started from two approximations: (1) 1 MW 20
000 PDMAEMA molecule should cover 75 nm2 of the cell
surface (based on the hydrodynamic diameter of PDMAEMA
in solution of 10 nm), and (2) the area of an RBC is 135 μm2.28
On the basis of these data, full coverage of the RBCs would
Figure 4. Contour plots showing localization of R1, R2, R3, and R4.
The y axis measures fluorescence, and the x axis indicates size
distribution. (A) Native RBCs incubated with aGPA. A homogeneous
cell population is located in R3. (B) P2-treated RBCs. A non-
homogenous population is observed. All cells located in R4 present
partial camouflage.
Figure 5. (A) Distribution of percentage of partially camouflaged,
noncamouflaged, and sensitized RBCs in a PDMAEMA-RBC
population represented by each bar. (B) % MFI Bars with (*):
significantly statistical differences between that sample and native
RBCs incubated with aGPA. Bars with (#): significantly statistical
differences between those samples and P2 at 10 μg/mL. A bar is the
average of at least two distinct replicas.
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need ∼1.7 million polycation molecules if they adsorb under
the form of a regular monolayer at the plasma membrane
surface. Considering the concentration of the RBC suspension
used for the coating (2.5% when diluted with the polycation
solution), we can readily calculate that the two polymer
concentrations used (i.e., 2 and 10 μg/mL) should correspond
to 50 and 250% of the total theoretical surface exposed by the
RBCs. Although this calculation is limited by the exact
conformation of the polycation macromolecules once adsorbed
to the membrane and of their compaction/surface density, the
estimate provides an approximate picture of the polyelectrolyte
molecules used to cover the cell membrane. This assumption
does not take into account the possible condensation of the
PDMAEMA upon its adsorption to the cell membrane surface
due to the formation of protein−polyelectrolyte complexes
with, as a result, a reduction in hydrodynamic diameter of the
synthetic polymer with an organization status, which should be
affected by the experimental conditions adopted during the
coating.29 Keeping in mind the limits of our assumption, our
experimental conditions should permit completely coating the
RBCs’ surface with a 10 μg/mL PDMAEMA concentration,
considering an association constant favorable for their
migration to the surface. In contrast with the apparent lack of
reactivity of PDMAEMA to the RBC, the existence of RBCs
with an increased percentage of FMI is astonishing.
With respect to PDMAEMA-induced sensitization, it is well
known that polycations such as protamine and polybrene
enhance RBCs’ antibody detection because of reduction in
intercellular distance facilitating agglutination.26,30 Therefore,
polycations act on the second stage of agglutination, that is,
agglutination by itself, but they do not influence the first stage,
sensitization.26 Surprisingly, taking into account the fact that
sensitized cells did not increase their size distribution (i.e., cells
located at Region 2), PDMAEMA-induced sensitization was
not due to cell aggregation. RBC sensitization could occur if the
synthetic polymer could promote attraction of aGPA, therefore,
through an increase in affinity of the antigen−antibody
interactions. From this point of view, it is worth reminding
that the antigen and antibody interaction is the result of the
nanometric interplay of these two entities with the establish-
ment of long-range ionic bonds and short-range hydrophobic
interactions that overcome the hydration energy of the antigen
and the antibody.26 Obviously it would not be surprising that
the precoating of the cell glycocalyx with PDMAEMA could
affect this antigen−antibody interplay by modifying at least the
local ionic environment and participate in increasing ionic
bonds on the RBC surface with aGPA. In addition to
participating in the control of ionic bonds on RBCs surface,
the hydrophobic and hydrophilic areas of the PDMAEMA
backbone, partially protonated at neutral pH,31 could also alter
the hydrophobicity/hydrophilicity ratio of the cell surface and
could promote the physical removal of water molecules to
facilitate aGPA binding.
3.3. Effect of PDMAEMA Copolymers on RBCs. Three
distinct PDMAEMA-co-MAPEG copolymers (Table 1) were
used to assess the ability of the PEG sequence to provide the
steric repulsion expected to increase the immunomasking
action. This comparison should allow us to explore the
influence of both the length of the PEG segments (oligomers
of MW 480 or 3050; comparing P3 and P4, respectively) and
the PEG distribution along the PDMAEMA backbone (palm
tree vs random distribution; comparing P3 and P4 vs P5,
respectively).
Riquelme et al. have noticed that those copolymers affected
the RBCs and induced aggregation at 125 μg/mL,15 we decided
to assess them at concentration below 100 μg/mL. Addition-
ally, taking into account the thermoresponsive properties of
PDMAEMA-based polymers,32 we compared the effect of three
temperatures (25 °C, 30 °C, and 37 °C) on immunomasking.
To facilitate the comparison of polycations hemoreactivity, we
integrated within Figure 6 the evolution of the percentages of
pcfRBCs, ncfRBCs, and sRBCs as a function of the three
variables, that is, nature and concentration of the copolymers
and temperature. From these data, it is straightforward to
notice that P5 has a behavior totally different from the other
copolymers but also compared with the homopolymers. Indeed,
whatever the conditions adopted, P5 did not significantly affect
the FACS signals measured from the coated RBCs. Hence,
although of short length, the PEG in P5 played a decisive role
in the lack of cell reactivity, in particular, by comparison to P3.
We expect that a statistical distribution of the PEG grafts along
the PDMAEMA backbone hampers the ionic interaction of the
copolymer on the RBC surface. In the case of polymers P3 and
P4, their PEG moieties are sufficiently separated from the
polycationic sequence. This pseudoblock copolymer structure is
therefore more favorable to anchor the PDMAEMA to the cell
plasma membrane while leaving the PEG extremity-free.
Clearly, architecture plays a major role in the adsorption of
polymer and camouflage ability of RBCs.
These antagonistic behaviors should definitely find their
origin in a modification in affinity for those copolymers having
Figure 6. Effect of temperature, nature, and concentration of
polycations on their immunomasking efficiency. The percentages of
pcfRBCs, ncRBCs, and sRBCs in a PDMAEMA-RBC population are
represented by each bar. (A) P3-treated samples, (B) P4-treated
samples, and (C) P5-treated samples.
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cell membranes affected by the temperature. From this point of
view, it is important to remind that the two polymer sequences
belonging to our polycations are well known to be
thermoresponsive with a lower critical solution temperature
(LCST) in aqueous solution of 30 to 40 °C and 100−150 °C
for PDMAEMA and PEO, respectively, depending on their Mw
and pH.33 For example, in the case of PDMAEMA, its full
protonation at lower pH does not allow its phase transition,
which is observed only at either neutral or basic pH. Beyond
this temperature, these polymers become insoluble in water, a
behavior that is typical for the polymers that form hydrogen
bonds to water. As a consequence, within this critical
temperature zone, the physicochemical state of the macro-
molecules drastically changes with, as a first step, the
conformational change of the molecules that undergoes coil-
to-globule transition before achieving within a second step the
cloud point, which can be macroscopically observed. Definitely
through this dehydration process of the polycations coming
from the breakage of the hydrogen bond, a decrease in polarity
of PDMAEMA should be observed with a temperature increase
and should promote their adsorption to RBCs membrane. This
change in macromolecule shape and hydrodynamic diameter in
this transition regime has been suggested to explain the
superior antibacterial activity of a PDMAEMA (Mw - 2 800)
around 37−43 °C compared with ambient temperature
(adsorption on cell membrane and perturbation).33
The temperature of phase transition of our copolymers
should be increased by the presence of the PEG grafts
compared with the homopolymer of DMAEMA. For example,
Ward et al. have reported a cloud point of 72 °C for PEGMA-
DMAEMA copolymer (with theoretical sequence lengths of
2920−6580, respectively) when dissolved in an aqueous
medium at pH 7.8.32 However, Jean et al. found that the
cloud point corresponds to the macroscopic phase separation of
thermoresponsive polymers that have already undergone
molecular conformational changes at lower temperatures.34 In
addition to this explanation, which needs support by a
physicochemical characterization of our polycation solutions,
we cannot rule out a kinetics contribution. Hence, the effect of
temperature is clarified because if that factor increases, then the
Brownian movement of molecules will also increase, promoting
contact between RBCs and PDMAEMAs and resulting in
higher polymer adsorption. Considering that temperature
increment has been reported as a factor enhancing polycation
adsorption,35 it might occur.
The effect of temperature on the MFI percentage has also
been calculated for samples treated with 100 μg/mL, thus
showing the highest percentage of pcfRBCs (Figure 7).
Interestingly, the copolymers reduced the percentage of MFI
to the same extent as that observed for the homopolymers at 10
μg/mL. These observations highlight that the PDMAEMA
sequence plays the major contribution in masking antigen
effectiveness, whereas the presence of the PEG moieties mostly
increases their protection efficiency within a given population
of RBCs.
In this respect, the PEG in the PDMAEMA backbone might
not have had the physical properties necessary for masking,
especially considering the size of the PEG chains. As reported
by Bradley et al., antigen size and MW of polymer are
important in the efficacy of immunocamouflage. For antigenic
determinants of Jka/Jkb blood groups farther out on from the
cell surface, the MW 5000 PEG was inefficient for masking; but
when MW (20 000) and density increased, the PEG covered
those antigenic sites.36
In our case, it was expected that PDMAEMAs exhibit enough
volume to cover the GPA extracellular antigenic domain having
a MW of 22 000. However, the protection does not depend
only on the covered volume. When immunoprotecting the
antigen surface, one should consider not only protection from a
dimensional standpoint but also the total exclusion volume for
diffusing the antibodies according to the volume occupied by
the antigenic structures of GPA, but once adsorbed, the
polycation molecule may change to conform to a more
restricted area of protection. For instance, on inert surfaces,
polycation adsorption may take the form of trains or loops,
depending on the difference in segment length between both
the cationic groups on the polycation backbone and the anionic
sites expressed at the surface.33,37 If a similar adsorption
behavior occurs on the RBC membrane, then we should also
take into account the fact that the RBC membrane is a living
system wherein the lateral mobility of proteins could
significantly influence charge redistribution.38 Therefore, poly-
cation adsorption on the RBC surface is not as predictable as
that on a static surface. This unpredictable behavior is apparent
in our study when we compared the protection effectiveness of
the three copolymers. Although P4 presented the longest PEG
chains (MW 3050), it did not induce a lowering MFI as it
might be expected according to the effect of the PEG MW on
camouflaging, as discussed above.
In addition to complexities of polycation−RBC interaction, it
should be noted that subject-to-subject variations may affect
polycation adsorption and their subsequent effects on the RBC
membrane. Even the heterogeneity of a cell population coming
from the same blood donor can affect the interaction between
RBCs and polycations. For instance, Sovadinova et al. have
observed that the effects of amphiphilic methacrylate
copolymers containing primary amino groups (MW of
copolymers: 2300−2800) on RBCs varied because of cell-to-
cell differences.39 A major finding of that study was that the
polycations induced nanoporosity in a heterogeneous pattern
from cell to cell. The researchers interpreted their observations
as a possible consequence of a variation in polymer adsorption
profile among cells due to an erythrocyte-to-erythrocyte
variation in sensitivity to pore formation.39 In the same
context, polymer-induced blood response variations have also
been reported by Armstrong et al., in this case regarding PEG-
and dextran-induced RBC aggregation.40 In addition to this
interindividual variability, the distribution of erythrocyte ages
within a given blood sample with associated biochemical and
Figure 7. Comparison of the immunomasking effectiveness of the
copolymers based on the % MFI of samples treated with polycations
P3, P4, and P5 (100 μg/mL). Samples with (*) showed significant
statistically differences respect to the control: RBCs/aGPA MFI %.
Samples with (#) showed significant statistically differences respect to
P5 at 37 °C.
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cellular age-dependent variations has been used to explain the
unpredictable polymer-induced blood response.40 Differences
in hemoreactivity to distinct synthetic polymers have been
reviewed by Rampling et al., who stressed the need to
investigate the sources of those membrane surface variations.41
4. CONCLUSIONS
In the perspectives of blood transfusion applications, but also
drug delivery system,42,43 we have compared the camouflaging
ability of PDMAEMA homopolymers and PDMAEMA-co-PEG
copolymers to cover RBCs. From this comparative study, the
following critical clear statements can be drawn.
If a repulsive action could already be expected from RBC’s
surface modified with PDMAEMA homopolymer,19 then only a
maximum of 10% of the whole RBCs were partially (up to
80%) masked by the largest PDMAEMA tested while
preventing nonspecific cell aggregation. The adoption of higher
Mw PDMAEMA should be avoided taking into account the fact
that this increase in size is detrimental in hemocompatibility.16
Interestingly enough above a Mw of 10 000 and a concen-
trations of 2 μg/mL PDMAMEA selectively enhances cell
agglutination following immune recognition of the GPA
antigens on the RBC surface, an observation that would
merit additional efforts in view to enhance immunodiagnostic
recognitions.
As expected, the PEG sequences of the palm-tree
architecture enhance the stability of the RBCs and allow us
to raise the immunomasking efficiency (up to 40%) but
without, however, achieving a full protection against Anti-GPA
recognition (maximum protection effectiveness of 80%). The
lack of difference in camouflage efficiency between copolymer
P3 and P4 suggests that the critical Mw to afford the steric
stabilization of RBCs is relatively short (∼480), whereas larger
polyethylene chains could perhaps contribute to improve their
effectiveness, that is, the extent of polymer covering per cell.
If the brush-like comb-polymer architecture of random
copolymer P5 could provide better steric performance with a
structure theoretically more favorable to stretch the polymer
backbone, while leaving the side-chains almost unstretched,
then in practice this copolymer would be less efficient than the
copolymers and the homopolymers. The random distribution
of PEG segments probably best impaired the adsorption of the
polycation backbone to the RBC’s membrane.
Interestingly enough, a sensitization in aGPA detection has
been highlighted for a given fraction of RBCs after incubation
with the polycations. This process, temperature-dependent and
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